Secondary Logo

January/February 2019 - Volume 39 - Issue 1
pp: 1-93



An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder

Simen, Arthur; Whitlock, Mark; Qiu, Ruolun; More

Journal of Clinical Psychopharmacology. 39(1):20-27, January/February 2019.

Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Surman, Craig; Ceranoglu, Atilla; Vaudreuil, Carrie; More

Journal of Clinical Psychopharmacology. 39(1):28-38, January/February 2019.

Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study

Göhler, Karin; Sokolowska, Marta; Schoedel, Kerri A.; More

Journal of Clinical Psychopharmacology. 39(1):46-56, January/February 2019.



Effectiveness of Venlafaxine in Selective Serotonin Reuptake Inhibitor–Resistant Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India

Balachander, Srinivas; Kodancha, Prabhath Gujjadi; Arumugham, Shyam Sundar; More

Journal of Clinical Psychopharmacology. 39(1):82-85, January/February 2019.


Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning–Based Treatment Outcome in Obsessive-Compulsive Disorder: A Pilot Study

Linkovski, Omer; Wheaton, Michael G.; Zwerling, Jordana; More

Journal of Clinical Psychopharmacology. 39(1):91-93, January/February 2019.